605. Identification of a Novel CMY-Variant Enzyme in a Clinical Escherichia coli Strain with Treatment-Emergent Ceftazidime–Avibactam Resistance

BACKGROUND: Ceftazidime–avibactam (CZA) is a novel β-lactam / β-lactamase inhibitor with in vitro activity against multidrug-resistant Gram-negatives, including those harboring CMY-2 enzymes. Treatment-emergent resistance to CZA has been described in KPC-producing Klebsiella pneumoniae but has not b...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Open Forum Infect Dis
Auteurs principaux: Aitken, Samuel L, Endres, Bradley T, Khan, Ayesha, Shropshire, William C, Borjan, Jovan, Bhatti, Micah M, Sahasrabhojane, Pranoti V, Doi, Yohei, Shields, Ryan K, Shelburne, Samuel A
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2019
Sujets:
Abstracts
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6811110/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.674
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires